#eisai — Public Fediverse posts

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk

A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals #eisai #health

Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings

Ebisu-jinja was established by Myōan Eisai (明菴栄西) in 1202 to act as guardian for Kennin-ji (then being built), and to thank the god Ebisu for saving him from a storm when returning from the mainland.

Eisai is credited with bringing the Rinzai school of Zen and the tradition of tea-drinking to Japan.

#明菴栄西 #Kenninji #建仁寺 #Eisai #zen #Rinzai

Japan's health ministry on Tuesday approved the production and sale of a new medicine for ALS, raising hopes among patients. https://www.japantimes.co.jp/news/2024/09/24/japan/science-health/japan-new-als-drug-approve/ #japan #sciencehealth #als #eisai #mecobalamin

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain

Britain's medicine regulator said Thursday that it approved a novel Alzheimer's drug developed jointly by Japanese drugmaker Eisai and U.S. partner Biogen. https://www.japantimes.co.jp/news/2024/08/23/japan/britain-eisai-drug/ #japan #eisai #alzheimers #drugs #uk

European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk

Europe's medicines watchdog has rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits. https://www.japantimes.co.jp/news/2024/07/27/japan/science-health/europe-watchdog-alzheimers-drug/ #japan #sciencehealth #eisai #alzheimer039s #aging #health #dementia #medicine

Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

The writings of the monks Eisai and Dogen sought to determine the proper way to live on this Earth, in harmony with the Way. https://www.japantimes.co.jp/news/2024/05/17/japan/history/joy-zen-japanese-history/ #japan #history #zenbuddhism #dogen #eisai #kamakuraperiod

Novo Nordisk owner buys majority stake in Austrian life science tools company—As sales of weight loss drugs skyrocket, the insulin market falters —Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA --http://bit.ly/w28kSd #novonordisk #mergersandacquisitions #insulin #diabetes #alzheimers #eisai #biogen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us

Teams of researchers from Niigata University and the University of Tokyo have begun an international clinical trial to check the effectiveness and safety of a treatment for familial Alzheimer's disease. https://www.japantimes.co.jp/news/2024/03/15/japan/science-health/familial-alzheimers-treatment-trial/ #japan #sciencehealth #alzheimer039s #eisai #pharmaceuticals

Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, according to a company spokesperson. https://www.japantimes.co.jp/business/2024/02/05/companies/eisai-alzheimers-drug-china/?utm_content=buffer2498b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #companies #eisai #pharmaceuticals #alzheimer039s #china

New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals

quote :
厚生勞動省（相當於衛生福利部）專家小組8月21日審核通過 #日本 #衛采製藥 （ #Eisai ）與 #美國 藥廠 #百健（ #Biogen ）合作開發的 #阿茲海默症 新藥 #Lecanemab （又稱為 #Leqembi ）。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

https://www.cna.com.tw/news/aopl/202309250285.aspx

A health ministry panel reviewing the new Alzheimer’s drug lecanemab greenlighted its approval in Japan on Monday. https://www.japantimes.co.jp/news/2023/08/21/japan/science-health/lecanemab-alzheimers-drug-approval/?utm_content=buffer356e4&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #lecanemab #eisai #alzheimer039s #pharmaceuticals #health

Drug giant Eisai's global Alzheimer drug program officer Ivan Cheung will be replaced by the son of the firm’s CEO, after a tenure that saw Cheung lead the push for U.S. approval of breakthrough medicine Leqembi. https://www.japantimes.co.jp/news/2023/07/11/business/corporate-business/eisai-alzheimers-leqembi-ivan-cheung-ceo-son-keisuke-naito/?utm_content=bufferfeb39&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #corporate #pharmaceuticals #alzheimers #eisai #keisukenaito

Eisai’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators, a move that will help widen insurance access to the first drug cleared based on its ability to slow progression of the mind-robbing disease. https://www.japantimes.co.jp/news/2023/07/07/world/science-health-world/eisai-alzherimers-drug-u-s-approval/?utm_content=buffer46a0b&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #us #health #brain #alzheimers #eisai #medicine

Expectations for the Alzheimer's treatment lecanemab are rising in Japan and it could be approved as early as fall, but even then there would be several barriers to its widespread adoption. https://www.japantimes.co.jp/news/2023/07/04/national/science-health/lecanemab-japan-approval-expectations/?utm_content=bufferb2b8f&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #japan #aging #elderly #pharmaceuticals #dementia #alzheimers #eisai #medicine

Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price. https://www.japantimes.co.jp/news/2023/06/19/world/science-health-world/europe-alzheimers-experts-doubt-eisai-biogen-drug/?utm_content=buffer28b58&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #health #brain #alzheimers #biogen #eisai

Nach Cyber-Angriff: #Ransomware-Befall bei Pharmaunternehmen #Eisai | Security https://www.heise.de/news/Ransomware-Angriff-Pharmaunternehmen-Eisai-nimmt-Systeme-offline-9182166.html #Malware #CyberCrime

FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)

The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda